More tumult at BIO amid the company’s fourth CEO in four years
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we see some holes in the data for MDMA-assisted therapy, and ponder how that might impact the FDA’s upcoming decision over its approval. Also, the agency’s advisers debate Guardant’s colon cancer liquid biopsy test, and we see new data showing Ozempic’s efficacy in preventing death in diabetes and chronic kidney disease patients.
Read Original Article: More tumult at BIO amid the company’s fourth CEO in four years »
